SCHEMBL2965033

SCHEMBL2965033

CCOC(=O)c1ccc2c(c1)ncn2-c1cccc(C(OC)c2ccncn2)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.48
HPGD P15428 10/20 0.46
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2966478 0.90 FGFR1 (0.52) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2969712 0.86 GABRA1 (0.51) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2977437 0.83 FGFR1 (0.48) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2964598 0.83 FGFR1 (0.48) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2977158 0.83 FGFR1 (0.48) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2652173 0.83 FGFR1 (0.50) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2652951 0.82 HPGD (0.38) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2654547 0.79 HPGD (0.46) FGFR1HPGDKMT2ASMN1; SMN2MAPK1
SCHEMBL2977538 0.78 HPGD (0.37) FGFR1HPGDGABRA1GABRG2GABRB3
SCHEMBL30343744 0.76 FGFR1 (0.75) FGFR1HPGDSMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 FGFR1 4324/4885HPGD 1855/4885KMT2A 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.